Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
67.29
-0.61 (-0.90%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gilead Sciences
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
45
46
Next >
Bank of America, Bank of New York Mellon And 2 Other Stocks Insiders Are Selling
July 24, 2023
The Nasdaq 100 closed slightly higher on Friday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
Expert Ratings for Gilead Sciences
July 24, 2023
Via
Benzinga
New Biktarvy® Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic
July 23, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities
July 23, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Peering Into Gilead Sciences's Recent Short Interest
July 19, 2023
Via
Benzinga
Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
July 18, 2023
Via
Benzinga
Price Over Earnings Overview: Gilead Sciences
July 17, 2023
Via
Benzinga
Governor DeSantis Says He Would Sue the Drug Company Gilead for Trying to Save Lives
July 23, 2023
DeSantis made it clear that he thinks companies should only maximize profit and be subject to shareholder lawsuits if they do anything other than maximizing profits. So how does this get us to suing...
Via
Talk Markets
Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS
July 21, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant From Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States
July 20, 2023
From
The Center for Disease Analysis Foundation
Via
Business Wire
Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S.
July 20, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States
July 20, 2023
From
CDA Foundation
Via
GlobeNewswire
2 Growth Stocks That Could Rocket 81% to 233% Higher, According to Wall Street
July 20, 2023
The investment bank analysts who follow these stocks think they could deliver enormous gains in the not-so-distant future.
Via
The Motley Fool
The 7 Most Undervalued Nasdaq Stocks to Buy Now: July 2023
July 19, 2023
The market is soaring, but there is still time to buy these seven undervalued Nasdaq stocks before they head higher.
Via
InvestorPlace
SARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?
July 19, 2023
By David Willey, Benzinga
Via
TheNewswire.com
Topics
Death
Exposures
COVID-19
Death
Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023
July 19, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
July 19, 2023
It helps to offer products everyone needs.
Via
The Motley Fool
SARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?
July 18, 2023
Read the latest report on NanoViricides here.
Via
Benzinga
Buying These 2 Stocks Is a Good Way to Hedge Against a Market Crash
July 17, 2023
These stocks are built to withstand a bear market.
Via
The Motley Fool
MarketBeat Week in Review – 7/10 - 7/14
July 15, 2023
As inflation moderates, Investors are optimistic for the second quarter earnings season and that optimism is evident in some of the top stories from this week
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Gilead Sciences to Release Second Quarter 2023 Financial Results on Thursday, August 3, 2023
July 14, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
FDA Approves Gilead's Remdesivir For COVID-19 Treatment Patients With Severe Renal Impairment
July 14, 2023
The FDA approved Gilead Sciences Inc's (NASDAQ: GILD) supplemental new drug application for using Veklury (remdesivir) in COVID-19 patients with severe renal impairment,
Via
Benzinga
FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis
July 14, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus
July 13, 2023
Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth.
Via
MarketBeat
Topics
Retirement
Exposures
Pension
3 Biotech Stocks to Buy for Long-Term Gains
July 13, 2023
The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors.
Via
MarketBeat
Topics
ETFs
Economy
Exposures
Interest Rates
Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries
July 13, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
7 Tech Stocks to Watch on July 14
July 12, 2023
Tech stocks are on the rise today ahead of the upcoming Nasdaq 100 rebalancing, the changes for which will be announced this Friday, July 14.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
July 12, 2023
Via
Benzinga
Nasdaq 100 Index Shake-Up Rattles High-Flying Stocks of 2023
July 12, 2023
The Nasdaq 100 index is set for a special rebalancing. Seven mega-cap stocks driving the market's gains, as well as other stocks, face weighting adjustments.
Via
MarketBeat
Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?
July 10, 2023
Read the latest report on NanoViricides here.
Via
Benzinga
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
45
46
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.